alexa An Oral Tolerogenic Vaccine Protects Macaques from SIV Infection without Eliciting SIV-Specific Antibodies nor CTLs | OMICS International
ISSN 2155-6113
Journal of AIDS & Clinical Research

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

An Oral Tolerogenic Vaccine Protects Macaques from SIV Infection without Eliciting SIV-Specific Antibodies nor CTLs

Marc HV Van Regenmortel*

CNRS, UMR7242–Institut de Recherche de l’Ecole de Biotechnologie de Strasbourg (IREBS), Université de Strasbourg, Illkirch 67400, France

*Corresponding Author:
Marc HV Van Regenmortel
CNRS, UMR7242–Institut de Recherche de
l’Ecole de Biotechnologie de Strasbourg (IREBS)
Université de Strasbourg
Illkirch 67400, France
E-mail:[email protected]

Received Date: January 16, 2013; Accepted Date: January 17, 2013; Published Date: January 22, 2013

Citation: Regenmortel MHVV (2013) An Oral Tolerogenic Vaccine Protects Macaques from SIV Infection without Eliciting SIV-Specific Antibodies nor CTLs. J AIDS Clin Res 4:e112. doi:10.4172/2155-6113.1000e112

Copyright: © 2013 Regenmortel MHVV. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of AIDS & Clinical Research

In the issue of Cell Reports of 27 December 2012 (Vol 2: 1736-1746) a French-Chinese tripartite collaboration between the Université Paris-Descartes (Dr. Jean-Marie Andrieu), the Institut de Recherche pour le Développementin Montpellier (Dr. Wei Lu) and the University of Guangzou in China (Dr. Song Chen) produced research results that are probably the most astonishing and revolutionary vaccine data published in 2012 [1].

Using the SIV model in Chinese macaques, the group headed by Jean-Marie Andrieu in Paris and Wei Lu in Montpellier were able to suppress the initial activation of SIV- positive CD4+ T-lymphocytes in vivo which is the crucial step that allows SIV to initiate replication and to establish infection. They used an oral vaccine made of inactivated SIVmac239 associated with a common commensal bacterium of the digestive tract know as Lactobacillus plantarum which is known to induce immunological tolerance to foreign antigens.

In contrast to what happens with all anti-viral vaccines, this oral tolerogenic vaccine elicited neither anti-SIV antibodies nor cytotoxic T-lymphocytes but induced instead a previously unrecognized class of SIV- specific, non-cytolytic CD8+ T-regulatory cells which prevented SIV+ CD4+ T-cell activation and suppressed SIV replication. By blocking SIV reverse transcription in CD4+ T-cells, the initial burst of virus replication was prevented and the vaccinated macaques were protected from infection. Of the 16 vaccinated macaques that were challenged intra-rectally 3 to 14 months later with the homologous SIV strain as well as with the heterologous strainSIV-B670, 15 were solidly protected from SIV challenge. Since CD4+ T-cell activation drives both the initial SIV and HIV-1 replication in macaques and humans respectively, it is plausible that such a tolerogenic vaccine may also be effective against HIV-1 in humans and this will be certainly be investigated in the near future, either as a preventive or therapeutic vaccine.

This remarkable and totally unexpected breakthrough was obtained by an investigator-driven research that was not funded by the usual governmental and large scale organizations that support most of the ongoing HIV vaccine research world-wide. It was sponsored by a private benefactor who funded the project to the tune of 13 million Euros. This illustrates once again that success in basic vaccine research is unpredictable and that “risky” projects based on unorthodox thinking may deserve as much funding as the “safe” projects that are often preferred because they abide by current fashionable paradigms.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • Global experts meet on STD - AIDS and Infectious Diseases
    May 30-31, 2018 Auckland, New Zealand
  • 6th World Congress on Control and Prevention of HIV/AIDS , STDs & STIs
    August 27-29, 2018 Zurich, Switzerland
  • 6th International Conference on HIV/AIDS , STDs and STIs
    October 29-30, 2018 San Francisco, USA

Article Usage

  • Total views: 11680
  • [From(publication date):
    February-2013 - May 25, 2018]
  • Breakdown by view type
  • HTML page views : 7911
  • PDF downloads : 3769
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

che[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7